GlassScriptPhysician profile
Denise L Epperson
NPI 1851440267
$956.98
in general payments reported to CMS, 2019-2025
15 companies · $822 in 2025
The $822 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $44.17 · 2024: $90.60 · 2025: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $956.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $191.97 | 2024-2025 | Lybalvi, Aristada, Vivitrol |
| Lundbeck LLC | $144.65 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $121.30 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.89 | 2025 | Caplyta |
| Noven Therapeutics, LLC | $77.13 | 2023-2025 | Xelstrym |
| Neurocrine Biosciences, INC. | $69.68 | 2025 | |
| Abbvie INC. | $69.42 | 2023-2025 | |
| Tris Pharma INC | $43.77 | 2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $33.93 | 2025 | Hetlioz, Fanapt |
| Teva Pharmaceuticals USA, INC. | $24.98 | 2025 | Austedo Xr |
| Bausch Health US, LLC | $22.25 | 2024 | Wellbutrin, Aplenzin |
| Axsome Therapeutics, INC. | $21.10 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $19.55 | 2024 | Spravato |
| Corium, LLC | $17.92 | 2025 | Azstarys |
| Neos Therapeutics, LP | $14.44 | 2025 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Epperson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.